|drug4086||Treatment and prophylaxis Wiki||1.00|
There is one clinical trial.
This study is a research project to evaluate the efficacy of hydroxychloroquine for post-exposure prophylaxis and early treatment of Covid-19. The intervention entails administering prophylactic hydroxychloroquine to all contacts (Study 1) and treating non severe confirmed cases with hydroxychloroquine (Study 2).
Description: Incidence of secondary PCR confirmed symptomatic Covid-19 episodes among contacts after high risk PCR+ exposureMeasure: Study 1- Clinical and virological outcome in exposed contacts Time: Up to 14 days after start of treatment
Description: Incidence of symptomatically compatible or a PCR-positive result regardless of symptomsMeasure: Study 1- Transmission of SARS-CoV-2 in exposed contacts Time: Up to 14 days after start of treatment
Description: Reduction of viral RNA load in nasopharyngeal swabs at days 3, and 7 after treatment start.Measure: Study 2- Virological outcome in index cases Time: Up to 7 days after start of treatment
Description: Time from randomization to complete resolution of symptoms at an extended 28-days follow-Measure: Study 2- Clinical outcome in index cases Time: Up to 28 days after start of treatment
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports